---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173169"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:16:28.942254+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma shareholders elect all 10 director nominees; all AGM proposals pass

## Summary
- All ten director nominees elected, with support ranging from 79.2% (Gregory Norden) to 99.7% (M. Germano Giuliani).
- Non-binding say-on-pay approved: 483.9M for (94.5% of votes cast excluding 22M broker non-votes).
- Ratification of Ernst & Young as independent auditor passed with 534.2M for (99.98%).
- UK statutory accounts and auditor reappointment also approved with >99% support; no broker non-votes on those proposals.

## SEC filing metadata
- accession: 0001193125-23-173169
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/d461066d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173169
- JSON: https://secwatch.observer/filing/0001193125-23-173169.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173169.txt

## Key facts
- Shareholder Votes
  Royalty Pharma plc shareholders approved To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 3. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm: For Against Abstain 534,159,940 122,640 68,717 There were no broker non-votes on this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To re-appoint Ernst & Young Chartered Accountants as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 6. To re-appoint Ernst & Young Chartered Accountants as the Company’s U.K. statutory auditor under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. annual report and accounts are presented to shareholders: For Against Abstain 534,146,610 136,605 68,082 There were no broker non-votes on this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2022 ("U.K. Annual Report and Acco at the 2023-06-22 meeting.
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 4. To approve receipt of the Company’s U.K. statutory accounts together with the Company’s U.K. statutory reports, including the directors’ report, the strategic report, the directors’ remuneration report and the auditors’ report for the fiscal year ended December 31, 2022 (“U.K. Annual Report and Accounts”) : For Against Abstain 533,634,007 83,848 633,442 There were no broker non-votes on this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To authorize the board of directors to determine the remuneration of the Company’s U.K. statutory auditor at the 2023-06-22 meeting.
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 7. To authorize the board of directors to determine the remuneration of the Company’s U.K. statutory auditor: For Against Abstain 534,177,160 97,715 76,422 There were no broker non-votes on this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To elect ten directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2024 Annual General Meeting of Shareholders at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 1. To elect ten directors, each by separate ordinary resolutions, to the Company’s Board of Directors to serve until the 2024 Annual General Meeting of Shareholders: Nominee For Against Abstain Broker Non-Votes Pablo Legorreta 502,375,930 9,675,993 245,006 22,054,368 Henry Fernandez 436,729,886 75,363,229 203,814 22,054,368 Bonnie Bassler, Ph.D. 508,838,926 3,265,116 192,887 22,054,368 Errol De Souza, Ph.D. 473,005,611 39,098,656 192,662 22,054,368 Catherine Engelbert 446,746,829 65,346,788 203,312 22,054,368 M. Germano Giuliani 510,728,863 1,394,714 173,352 22,054,368 David Hodgson 499,416,709 12,686,655 193,565 22,054,368 Ted Love, M.D. 503,788,473 8,315,977 192,479 22,054,368 Gregory Norden 425,957,451 86,156,645 182,833 22,054,368 Rory Riggs 510,716,352 1,408,407 172,170 22,054,368
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts at the 2023-06-22 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 5. To approve, on a non-binding advisory basis, the Company’s U.K. directors’ remuneration report in the U.K. Annual Report and Accounts: For Against Abstain Broker Non-Votes 483,001,347 29,165,130 130,452 22,054,368
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm
- Shareholder Votes
  Royalty Pharma plc shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-22 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 483,910,458 28,152,706 233,765 22,054,368
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312523173169/0001193125-23-173169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.